De Luca D, Minucci A, Cogo P, Capoluongo ED, Conti G, Pietrini D, et al. (January 2011). "Secretory phospholipase AA2 pathway during pediatric acute respiratory distress syndrome: a preliminary study". Pediatric Critical Care Medicine. 12 (1): e20–e24. doi:10.1097/PCC.0b013e3181dbe95e. PMID20351613. S2CID36962872.
Ezzeddini R, Darabi M, Ghasemi B, Jabbari Moghaddam Y, Jabbari Y, Abdollahi S, et al. (April 2012). "Circulating phospholipase-A2 activity in obstructive sleep apnea and recurrent tonsillitis". International Journal of Pediatric Otorhinolaryngology. 76 (4): 471–474. doi:10.1016/j.ijporl.2011.12.026. PMID22297210.
Six DA, Dennis EA (October 2000). "The expanding superfamily of phospholipase A(2) enzymes: classification and characterization". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1488 (1–2): 1–19. doi:10.1016/S1388-1981(00)00105-0. PMID11080672. S2CID23717374.
Tellis CC, Tselepis AD (May 2009). "The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma". Biochimica et Biophysica Acta. 1791 (5): 327–338. doi:10.1016/j.bbalip.2009.02.015. PMID19272461.
Berg OG, Gelb MH, Tsai MD, Jain MK (September 2001). "Interfacial enzymology: the secreted phospholipase A(2)-paradigm". Chemical Reviews. 101 (9): 2613–2654. doi:10.1021/cr990139w. PMID11749391. See page 2640
PDB: 1FXF; Pan YH, Epstein TM, Jain MK, Bahnson BJ (January 2001). "Five coplanar anion binding sites on one face of phospholipase A2: relationship to interface binding". Biochemistry. 40 (3): 609–617. doi:10.1021/bi002514g. PMID11170377.
Farooqui AA, Ong WY, Horrocks LA (September 2006). "Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders". Pharmacological Reviews. 58 (3): 591–620. doi:10.1124/pr.58.3.7. PMID16968951. S2CID6137443.
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC (October 2004). "Essential fatty acids and phospholipase A2 in autistic spectrum disorders". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 71 (4): 201–204. doi:10.1016/j.plefa.2004.03.008. PMID15301788.
Law MH, Cotton RG, Berger GE (June 2006). "The role of phospholipases A2 in schizophrenia". Molecular Psychiatry. 11 (6): 547–556. doi:10.1038/sj.mp.4001819. PMID16585943.
De Luca D, Minucci A, Cogo P, Capoluongo ED, Conti G, Pietrini D, et al. (January 2011). "Secretory phospholipase AA2 pathway during pediatric acute respiratory distress syndrome: a preliminary study". Pediatric Critical Care Medicine. 12 (1): e20–e24. doi:10.1097/PCC.0b013e3181dbe95e. PMID20351613. S2CID36962872.
Ezzeddini R, Darabi M, Ghasemi B, Jabbari Moghaddam Y, Jabbari Y, Abdollahi S, et al. (April 2012). "Circulating phospholipase-A2 activity in obstructive sleep apnea and recurrent tonsillitis". International Journal of Pediatric Otorhinolaryngology. 76 (4): 471–474. doi:10.1016/j.ijporl.2011.12.026. PMID22297210.
Six DA, Dennis EA (October 2000). "The expanding superfamily of phospholipase A(2) enzymes: classification and characterization". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1488 (1–2): 1–19. doi:10.1016/S1388-1981(00)00105-0. PMID11080672. S2CID23717374.
Tellis CC, Tselepis AD (May 2009). "The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma". Biochimica et Biophysica Acta. 1791 (5): 327–338. doi:10.1016/j.bbalip.2009.02.015. PMID19272461.
Berg OG, Gelb MH, Tsai MD, Jain MK (September 2001). "Interfacial enzymology: the secreted phospholipase A(2)-paradigm". Chemical Reviews. 101 (9): 2613–2654. doi:10.1021/cr990139w. PMID11749391. See page 2640
PDB: 1FXF; Pan YH, Epstein TM, Jain MK, Bahnson BJ (January 2001). "Five coplanar anion binding sites on one face of phospholipase A2: relationship to interface binding". Biochemistry. 40 (3): 609–617. doi:10.1021/bi002514g. PMID11170377.
Farooqui AA, Ong WY, Horrocks LA (September 2006). "Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders". Pharmacological Reviews. 58 (3): 591–620. doi:10.1124/pr.58.3.7. PMID16968951. S2CID6137443.
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC (October 2004). "Essential fatty acids and phospholipase A2 in autistic spectrum disorders". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 71 (4): 201–204. doi:10.1016/j.plefa.2004.03.008. PMID15301788.
Law MH, Cotton RG, Berger GE (June 2006). "The role of phospholipases A2 in schizophrenia". Molecular Psychiatry. 11 (6): 547–556. doi:10.1038/sj.mp.4001819. PMID16585943.
PDB: 1FXF; Pan YH, Epstein TM, Jain MK, Bahnson BJ (January 2001). "Five coplanar anion binding sites on one face of phospholipase A2: relationship to interface binding". Biochemistry. 40 (3): 609–617. doi:10.1021/bi002514g. PMID11170377.
semanticscholar.org
api.semanticscholar.org
De Luca D, Minucci A, Cogo P, Capoluongo ED, Conti G, Pietrini D, et al. (January 2011). "Secretory phospholipase AA2 pathway during pediatric acute respiratory distress syndrome: a preliminary study". Pediatric Critical Care Medicine. 12 (1): e20–e24. doi:10.1097/PCC.0b013e3181dbe95e. PMID20351613. S2CID36962872.
Six DA, Dennis EA (October 2000). "The expanding superfamily of phospholipase A(2) enzymes: classification and characterization". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1488 (1–2): 1–19. doi:10.1016/S1388-1981(00)00105-0. PMID11080672. S2CID23717374.
Farooqui AA, Ong WY, Horrocks LA (September 2006). "Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders". Pharmacological Reviews. 58 (3): 591–620. doi:10.1124/pr.58.3.7. PMID16968951. S2CID6137443.